108 related articles for article (PubMed ID: 3904417)
1. Immunofluorescent plasma cell labeling indices (LI) using a monoclonal antibody (BU-1).
Greipp PR; Witzig TE; Gonchoroff NJ
Am J Hematol; 1985 Nov; 20(3):289-92. PubMed ID: 3904417
[TBL] [Abstract][Full Text] [Related]
2. Multiple myeloma plasma cell kinetics: rapid and reliable evaluation using 5-bromo-2-deoxyuridine (BrdUrd) DNA incorporation detected by an anti-BrdUrd monoclonal antibody.
Boccadoro M; Redoglio V; Gavarotti P; Pileri A
Tumori; 1986 Apr; 72(2):135-7. PubMed ID: 3705185
[TBL] [Abstract][Full Text] [Related]
3. Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies.
Greipp PR; Witzig TE; Gonchoroff NJ; Habermann TM; Katzmann JA; O'Fallon WM; Kyle RA
Mayo Clin Proc; 1987 Nov; 62(11):969-77. PubMed ID: 3118117
[TBL] [Abstract][Full Text] [Related]
4. Rapid S-phase determination of non-Hodgkin's lymphomas with the use of an immunofluorescence bromodeoxyuridine labeling index procedure.
Witzig TE; Gonchoroff NJ; Greipp PR; Katzmann JA; Stenson MJ; Habermann TM; Colgan JP; Therneau TM; Banks PM
Am J Clin Pathol; 1989 Mar; 91(3):298-301. PubMed ID: 2646907
[TBL] [Abstract][Full Text] [Related]
5. The use of FITC-conjugated monoclonal antibodies for determination of S-phase cells with fluorescence microscopy.
Gunduz N
Cytometry; 1985 Nov; 6(6):597-601. PubMed ID: 3933924
[TBL] [Abstract][Full Text] [Related]
6. A monoclonal antibody reactive with 5-bromo-2-deoxyuridine that does not require DNA denaturation.
Gonchoroff NJ; Greipp PR; Kyle RA; Katzmann JA
Cytometry; 1985 Nov; 6(6):506-12. PubMed ID: 3905299
[TBL] [Abstract][Full Text] [Related]
7. Determination of the plasma cell labelling index with bromodeoxyuridine in a double fluorescence technique.
Lokhorst HM; Boom SE; Bast BJ; Ballieux RE
Br J Haematol; 1986 Oct; 64(2):271-5. PubMed ID: 3535868
[TBL] [Abstract][Full Text] [Related]
8. Plasma cell proliferation in monoclonal gammopathies: measurement using BU-1 antibody in flow cytometry and microscopy: comparison with serum thymidine kinase.
Schambeck CM; Wick M; Bartl R; Lamerz R; Fateh-Moghadam A
J Clin Pathol; 1995 May; 48(5):477-81. PubMed ID: 7629298
[TBL] [Abstract][Full Text] [Related]
9. [The bromodeoxyuridine index in multiple myeloma. I. Relation with selected laboratory indicators of the disease].
Scudla V; Ordeltová M; Bacovský J; Spidlová A; Budíková M; Kubalová D; Zivná J
Vnitr Lek; 1996 Jul; 42(7):458-62. PubMed ID: 8928421
[TBL] [Abstract][Full Text] [Related]
10. Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy.
Boccadoro M; Gavarotti P; Fossati G; Pileri A; Marmont F; Neretto G; Gallamini A; Volta C; Tribalto M; Testa MG
Br J Haematol; 1984 Dec; 58(4):689-96. PubMed ID: 6518137
[TBL] [Abstract][Full Text] [Related]
11. Proliferation kinetics of plasma cells and of normal haemopoietic cells in multiple myeloma.
Ucci G; Riccardi A; Dörmer P; Danova M; Luoni R; Montecucco CM; Ciotti R; Girino M
Cell Tissue Kinet; 1987 May; 20(3):311-8. PubMed ID: 3480077
[TBL] [Abstract][Full Text] [Related]
12. Determination of the growth fraction in monoclonal gammopathy with the monoclonal antibody Ki-67.
Lokhorst HM; Boom SE; Terpstra W; Roholl P; Gerdes J; Bast BJ
Br J Haematol; 1988 Aug; 69(4):477-81. PubMed ID: 3044442
[TBL] [Abstract][Full Text] [Related]
13. Characterization of myeloma cells by means of labeling index, bone marrow histology, and serum beta 2-microglobulin.
Schambeck CM; Bartl R; Höchtlen-Vollmar W; Wick M; Lamerz R; Fateh-Moghadam A
Am J Clin Pathol; 1996 Jul; 106(1):64-8. PubMed ID: 8701935
[TBL] [Abstract][Full Text] [Related]
14. Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma.
Greipp PR; Katzmann JA; O'Fallon WM; Kyle RA
Blood; 1988 Jul; 72(1):219-23. PubMed ID: 3291982
[TBL] [Abstract][Full Text] [Related]
15. Induction of serum stimulation and plasma cell proliferation during chemotherapy of multiple myeloma.
Karp JE; Burke PJ; Humphrey RL
Blood; 1977 Jun; 49(6):925-34. PubMed ID: 861376
[TBL] [Abstract][Full Text] [Related]
16. Lack of correlation between plasma cell thymidine labelling index and serum beta-2-microglobulin in monoclonal gammopathies.
Boccadoro M; Durie BG; Frutiger Y; Gavarotti P; Redoglia V; Massaia M; D'Alberto M; Marmont F; Gallamini A; Tribalto M
Acta Haematol; 1987; 78(4):239-42. PubMed ID: 3122489
[TBL] [Abstract][Full Text] [Related]
17. The labelling index of primitive plasma cells determines the clinical behaviour of patients with myelomatosis.
Joshua D; Petersen A; Brown R; Pope B; Snowdon L; Gibson J
Br J Haematol; 1996 Jul; 94(1):76-81. PubMed ID: 8757512
[TBL] [Abstract][Full Text] [Related]
18. Immunocytochemical evaluation of the percentage of proliferating cells in pathological bone marrow and peripheral blood samples with the Ki-67 and anti-bromo-deoxyuridine monoclonal antibodies.
Falini B; Canino S; Sacchi S; Ciani C; Martelli MF; Gerdes J; Stein H; Pileri S; Gobbi M; Fagioli M
Br J Haematol; 1988 Jul; 69(3):311-20. PubMed ID: 3165668
[TBL] [Abstract][Full Text] [Related]
19. Plasmablastic transformation of multiple myeloma.
Lee CK; Ma ES; Shek TW; Lam CC; Au WY; Wan TS; Chan LC
Hum Pathol; 2003 Jul; 34(7):710-4. PubMed ID: 12874768
[TBL] [Abstract][Full Text] [Related]
20. Cytoplasmic Immunoglobulin Light Chain Revelation and Interphase Fluorescence In Situ Hybridization in Myeloma.
Moore S; Suttle JM; Nicola M
Methods Mol Biol; 2017; 1541():127-142. PubMed ID: 27910020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
